Last reviewed · How we verify

PETROLATUM, WHITE

FDA-approved approved ✓ Verified May 2026 Quality 2/100

PETROLATUM, WHITE is a drug. It is currently FDA-approved (first approved 2006).

PETROLATUM, WHITE is a component used in various treatments, including the treatment of Verruca Plana, as seen in a clinical trial (NCT05314127) comparing its efficacy to Topical 5-Fluorouracil and Imiquimod. The exact mechanism of PETROLATUM, WHITE is currently unknown, as indicated by ChEMBL.

At a glance

Generic namePETROLATUM, WHITE
PhaseFDA-approved
First approval2006

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PETROLATUM, WHITE

What is PETROLATUM, WHITE?

PETROLATUM, WHITE is a pharmaceutical drug.

When was PETROLATUM, WHITE approved?

PETROLATUM, WHITE was first approved on 2006.

What development phase is PETROLATUM, WHITE in?

PETROLATUM, WHITE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing